 "WNS to acquire Value Edge Research Services")
NYSE-listed business process management firm WNS, with operations in India, on Friday announced that it has entered into a definitive agreement to acquire Value Edge Research Services, provider of commercial research and analytics services to clients in the Pharma / Biopharma industry. The financial details of the deals were not disclosed.
Value Edge provides consulting grade marketing and data analytics to globally leading bio-pharma companies.
“The acquisition of Value Edge deepens our domain and specialized analytical capabilities in the growing pharma market, and provides WNS with a technology asset which is leverageable across clients and industries,” said Keshav Murugesh, WNS’ Chief Executive Officer.
Value Edge has created a cloud-based platform designed to provide clients with competitive intelligence (CI) to drive strategic decision-making. Core company offerings include CI, opportunity assessment, forecasting, reporting & dash-boarding, modeling, business intelligence (BI) tool building, and data analysis. The company also provides services in the areas of pricing analytics, patient data analysis, key account management (KAM), sales force effectiveness (SFE), and social media monitoring.
“Value Edge is excited to partner with WNS, and the combination of our firm’s respective capabilities will enable us to help clients in the Pharma / Bio-Pharma industry improve their competitive positioning,” said Rohit Anand, Value Edge’s Founder and Managing Director. “We believe WNS’ global size and strength will allow us to tap new areas of demand, drive deeper relationships and expand our offerings.”
The acquisition of Value Edge is subject to Reserve Bank of India (RBI) approval and other customary closing conditions, and is expected to close in the first quarter of fiscal 2017. Value Edge currently employs over 100 people in India, the United States and Europe.
